Abstract: Disclosed are compositions and methods for the biocompatible sterilization of materials, in particular, of medical devices and implants. Sterilization is achieved by deactivation of microorganisms through treatment of the material with a mixture of at least one microbiocidal additive and a high-pressure or supercritical fluid, for example, high-pressure carbon dioxide or supercritical carbon dioxide. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present invention relates to the use in animal feed of a xylanase having a percentage of identity to a Paenibacillus xylanase having the sequence of amino acids 1-184 of SEQ ID NO: 4 of at least 82.7%, as well as to feed additives and feed compositions comprising such xylanase. These xylanases are significantly better than known animal feed xylanases to solubilize and also degrade insoluble fibre polysaccharides (Non-Starch Polysaccharides, abbreviated NSP), such as arabinoxylan polysaccharides.

Abstract: The present invention provides a novel liquid composition suitable for in-situ formation of a depot system to deliver a bioactive substance in a controlled manner. The composition of the present invention comprises: (a) a hydrophobic non-polymeric carrier material; (b) a water miscible biocompatible organic solvent that dissolves the hydrophobic non-polymeric material; (c) an ionic complex that is formed between an amphiphilic molecule and a bioactive substance having a net charge at neutral pH in water. The present invention also provides a method of manufacturing and use of the composition thereof.

Abstract: Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural ? amyloid peptides (?-AP). In a preferred embodiment, the ? amyloid modulator compounds of the invention are comprised of an A? aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural ? amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural ?-AP aggregation when the natural ?-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.

Abstract: Methods of modulating uptake of extracellular lysosomal enzymes by administering a pharmaceutical agent and methods of treating a lysosomal storage disease (such as Gaucher disease, Pompe disease, Fabry disease or Niemann-Pick disease) or enhancing enzyme replacement therapy or gene therapy, comprising administering a pharmaceutical agent such as dexamethasone, glucose or insulin, are provided.

Abstract: Use of cationic surfactants, derived from the condensation of fatty acids and esterified dibasic amino acids, of the formula (1): occasionally leads to a bitter taste, when the compound is present in a large concentration. The bitter taste can be masked by combination with a second component selected from the list consisting of sucralose, neohespiridin (NHDC), ?-cyclodextrin, mono ammonium glycyrrhizinate (MAG), banana, mentholyptus, sodium dodecyl sulphate (SDS), anetol, menthol, thaumatin, adenosine monophosphate (AMP), aloten, arginine, sodium acetate, arilic acids (ferulic acid, caffeic acid), sclareolide, maltol, anane, phosphatidic acid, eucalyptol, lactisole, lysozyme, lactoglobulin, timol, borneol, acetol, phosphothreonine, phosphotyrosine, phosphoserine, Masking flavour 501521T, Masking flavour 501522, saccharine, aspartame, MK22 N&A FL for masking #25682, MM24 Prosweet N&A FL Enhancer, neodiosmin, xylitol, stevia and Natural and Functional Flavour (NAF®).

Abstract: The invention concerns a nucleic acid encoding a recombinant bifunctional fusion peptidoglycan hydrolase protein formed from a nucleic acid encoding a peptidoglycan hydrolase module and a nucleic acid encoding a second peptidoglycan hydrolase module. The fusion, dual (or multiples thereof) peptidoglycan hydrolase modules can be used to treat disease caused by the bacteria for which the individual modules of the fusion protein are specific.

Abstract: The present invention provides a mimetic egg comprising lysozyme, a salt or biological fragment thereof or a lysozyme-related peptide and an active ingredient in its base material mimicking an egg of a vermin; and a vermin exterminating method using the mimetic egg.

Abstract: Use of recombinant human lysozyme in the preparation of a medicament for controlling life-threatening diseases associated with abnormal cell proliferation and migration, such as cancer metastasis, by administering to a subject in need thereof therapeutically effective doses of recombinant human lysozyme to elicit said antiproliferative and antimetastatic effects.

Abstract: The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10 mg/kg body weight per week to a patient.

Abstract: This invention relates to compositions and methods for providing cosmetic and other potential benefits to keratin-containing substrates. The compositions contain at least one naturally-occurring cationic protein with a biological function in a cosmetically acceptable carrier, such that the naturally-occurring cationic protein retains its essential configuration, preserving its biological function, when it is in proximity to a keratin-containing substrate.

Abstract: Methods and combinations are provided for controlling the duration of action, in vivo, of matrix-degrading enzymes. The methods and combinations permit temporary in-vivo activation of matrix-degrading enzymes upon administration to the extra cellular matrix (or “ECM”). Matrix-degrading enzymes having a controlled duration of action can be used to treat ECM-mediated diseases or disorders characterized by increased deposition or accumulation of one or more ECM components.

Abstract: The invention relates to an agent with increased thermal stability comprising a core and a coating layer characterized in that the core comprises at least one biologically active protein and that the coating layer comprises a micronized product from leguminous plants, a method for the production of this agent as well as the use of a micronized product from leguminous plants to increase the thermal stability of biologically active proteins in methods for the production of a granulated product as well as in methods for the production of animal feed, food and pharmaceuticals.

Abstract: A cosmetic use of at least one C-glycoside derivative in a composition comprising a physiologically acceptable medium, as a cosmetic agent for promoting the desquamation of the skin and/or the scalp and/or for stimulating epidermal renewal.

Abstract: This invention relates to molecular and cellular biology and biochemistry. In one aspect, the invention provides polypeptides having cellulase activity, e.g., endoglucanase, cellobiohydrolase, mannanase and/or ?-glucosidase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides cellulase activity, e.g., endoglucanase, cellobiohydrolase, mannanase and/or ?-glucosidase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural, food and feed processing and industrial contexts.

Abstract: The present invention relates, generally, to oral formulations including one or more recombinantly-produced human milk proteins. The formulations of the present invention may be used to prevent the onset of diarrhea in patients who have been or will be exposed to one or more agents known to cause diarrhea, and to prevent the recurrence of diarrhea in a patient recovering therefrom. The formulations may also be used in the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. The formulations may also be beneficially administered in accordance with methods for promoting the development of healthy intestinal flora in a human patient.

Abstract: The invention relates to the use of at least one bacterial amylase in feed for ruminant animals of the subfamily Bovinae in particular for improving milk yield, apparent digestibility of the diet fed, feedstuff dry matter disappearance, weight gain, and/or Feed Conversion Ratio (FCR). Examples of bovine animals are dairy cows and beef cattle. The invention also relates to the use of such amylases in feed and feed additives such as premix, concentrates and total mixed ration (TMR). The amylase may be used in combination with cellulase for improving milk yield and/or back fat thickness. Preferred amylases are derived from Bacillus halmapalus, licheniformis, and stearothermophilus and are preferably homologous to Bacillus stearothermophilus amylase.

Abstract: A composition for prophylactic and/or therapeutic medicinal applications, or plant protection applications, in particular for the control of microorganisms, either planktonic or organized in biofilms. The composition includes at least one ion selected from hypohalite, at least one compound selected from lactoferrin, lactoferrin peptide, lysozyme, immunoglobulins or a combination thereof, optionally hypothiocyanite, and optionally at least one growth factor.

Abstract: A xylanase gene, denoted xynR8, encoding a xylanase (XynR8) obtained from the unisolated rumen microorganisms is provided. The DNA sequence of the xynR8 gene, xylanase, is also provided, the enzyme is thermostable, and highly specific for xylans with high activity. Transformation of microbial hosts with the xynR8 gene is described. A method for degrading the xylan-containing structure comprises hydrolyzing the ?-1,4-glycosidic bonds of xylans by contacting xylanase is provided, and a composition employing the above-mentioned hydrolyzing method is further addressed.

Abstract: Therapeutic compositions include peptide formulations having a mixture of serum, albumin, casein, peptone, pacreatin, and sodium hydroxide. The peptide compositions do not include nucleic acid or any derivatives thereof. The peptide compositions have beneficial therapeutic properties to boost human immune system and to treat various ailments including malaria, allergy and inflammation. The peptide compositions, one having a molecular weight greater than 10 kDa and having amino acid residues in a range of 27 and 315, and the other having a molecular weight equal to or less than 10 kDa and amino acid residues in a range of 27 and 54, their structures and therapeutic properties are discussed.

Abstract: Provided are combinations, compositions and kits containing an fast-acting insulin composition and a hyaluronan degrading enzyme composition formulated for parenteral administration. Such products can be used in methods of treating insulin-treatable diseases or conditions. Also provided are methods for administration of a fast-acting insulin and a hyaluronan degrading enzyme.

Abstract: This invention relates to a polypeptide obtainable from insect larvae, such as those from Lucilia sericata, and which have activity as a nuclease in that they are able to degrade, denature, digest, cut or cleave nucleic acids such as DNA.

Abstract: The invention provides means and methods for vascular regulation through enhancement or inhibition of R-Ras activity. The invention specifically provides means and methods for promoting a quiescent state of a vascular cell by providing additional R-Ras activity to the cell. The invention further provides means and methods for diagnosing a condition of vasculature of an individual.

Abstract: It is an object of the present invention to provide an enzyme preparation which is excellent in stability in blood (blood residence) and in transfer to a target organ (targeting property), and can be used effectively in enzyme replacement therapy or the like. This problem is solved by a lipid vesicle composition wherein vesicles composed of a lipid bilayer membrane are encapsulating an enzyme, the composition being capable of retaining stably the activity of the enzyme even outside the stable pH range of the enzyme.

Abstract: Disclosed are compositions and methods for treating nephrogenic diabetes insipidus and for induction of diuretic effect.

Abstract: This invention relates to novel enzymes and novel methods for producing the same. More specifically this invention relates to a variety of fungal enzymes. Nucleic acid molecules encoding such enzymes, compositions, recombinant and genetically modified host cells, and methods of use are described. The invention also relates to a method to convert lignocellulosic biomass to fermentable sugars with enzymes that degrade the lignocellulosic material and novel combinations of enzymes, including those that provide a synergistic release of sugars from plant biomass. The invention also relates to methods to use the novel enzymes and compositions of such enzymes in a variety of other processes, including washing of clothing, detergent processes, deinking and biobleaching of paper and pulp, and treatment of waste streams.

Abstract: Embodiments of the present invention relate to atomic coordinates for PME-1 alone or in complex with PP2A, as well as methods for using these atomic coordinates to prepare inhibitors of PME-1 and/or PP2A and inhibitors prepared using such methods. Further embodiments relate to biochemical analyses of the interactions of PME-1 alone or in complex with PP2A. Further embodiments relate to compositions including mimetics and small molecules, optionally, secondary agents, which may be used to treat disorders in which PME-1 and/or PP2A activity plays a contributing role.

Abstract: A process for the preparation of an enzyme-containing granulate is disclosed where an aqueous enzyme-containing liquid is mixed with an edible carbohydrate-based solid carrier, such as starch, mechanically processed into granules, and subsequently dried. This enzyme granulate is suitable for the manufacture of animal feed compositions by mixing feed ingredients with the granulate, treating with steam and pelleting. The compositions optimally show improved enzyme stability during the pelleting process.

Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.

Abstract: This disclosure provides methods and compositions for the promotion of enzymatic activity of Target Enzymes, including but not limited to oligosaccharide/polysaccharide enzymes, protein enzymes, polynucleotide enzymes. The methods involve use of a non-naturally occurring polysaccharide (including but not limited HES) for promoting the enzymatic activity of an enzyme in liquid milieu, wherein the concentration of the polysaccharide in the composition comprising the Target Enzyme is from about 0.01% to about 55% w/v.

Abstract: The present invention is directed to compositions and methods for non-irritatively treating and preventing non-invasive fungus-induced mucositis. Specifically, the invention involves compositions including a mucosally non-irritative mixture of amphotericin B and a pharmaceutically acceptable carrier. Such compositions can be non-irritatively mucoadministered to prevent, reduce, or eliminate chronic non-invasive fungus-induced mucositis conditions.

Abstract: Laminitis is defined as an inflammation of the sensitive laminae of the hoof, especially in horses. It has been surprisingly found that fructanases such as 2,1-?-D-fructan hydrolase are highly effective as therapeutic and prophylactic agents against laminitis in horses. The fructanases may be used as enzyme compositions in horse feed, as additives for horse feed or as oral preparations for the therapy and prophylaxis of laminitis. Because of its effectiveness in hydrolyzing fructans, which seem to play an important role in the aetiology of laminitis, the administration of fructanases in combination with an increased intake of fructans or with an increased availability of fructans is particularly advantageous.

Abstract: The present invention relates generally to methods for promoting regeneration, outgrowth and survival of dopaminergic neurons comprising contacting said dopaminergic neurons with an effective amount of a composition comprising an Sp35 antagonist. Additionally, the invention is related generally to methods of treating various diseases, disorders or injuries associated with dopaminergic neuronal degeneration or death by administration of an Sp35 antagonist.

Abstract: The present invention provides highly impact-resistant, water-soluble or water dispersible, low-dust granules comprising an active ingredient and methods for obtaining the same.

Abstract: The present invention provides a composition comprising one or more of a matrix metalloprotease inhibitor, a de-carboxylase inhibitor, a fructanase enzyme and/or a flavonoid for use in the prevention of laminitis

Abstract: The invention provides polypeptides having any cellulolytic activity, e.g., a cellulase activity, a endoglucanase, a cellobiohydrolase, a beta-glucosidase, a xylanase, a mannanse, a ?-xylosidase, an arabinofuranosidase, and/or an oligomerase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides having any cellulolytic activity, e.g., a cellulase activity, e.g., endoglucanase, cellobiohydrolase, beta-glucosidase, xylanase, mannanse, ?-xylosidase, arabinofuranosidase, and/or oligomerase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. In one aspect, the invention provides polypeptides having an oligomerase activity, e.g., enzymes that convert recalcitrant soluble oligomers to fermentable sugars in the saccharification of biomass.

Abstract: A skin care composition comprising at least one keratinocyte CLOCK or PER1 gene activator and at least one DNA repair enzyme; a method for inhibiting damage to human keratinocytes due to environmental aggressors by applying a composition comprising at least one keratinocyte CLOCK or PER1 gene activator and at least one DNA repair enzyme; and a method for repairing DNA damage in human keratinocytes.

Abstract: Digestible compositions of inulin for managing blood glucose levels in a patient are disclosed. The compositions can include an inulin, a sucrose and an amylase, wherein the inulin is configured to lower blood glucose in the patient and wherein the sucrose is presented in sufficient amount to at least partially counteract the blood glucose lowering effect of the inulin. Several embodiments disclosed in the present application include a vegetable mixture comprising burdock root, carrots and daikon radish and additional constituents such as dimethyl sulfoxide, lentinan and D-eritadenine. Additionally, methods of preparing a digestible composition of inulin are also disclosed.

Abstract: Orally administered physiologically acceptable anti-biofilm compositions comprising enzymes and if desired additional components such as antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of gastrointestinal biofilm infections, and associated systemic symptoms caused by biofilms associated microorganisms within the gastrointestinal tract. Methods of identification, preparation and use of such physiologically acceptable anti-biofilm compositions are also provided.

Abstract: The present invention relates to agents for suppressing pulmonary emphysematous lesions and agents for suppressing emphysematous lesions which are suitable for treating and/or preventing COPD, which comprise as an active ingredient a substance having an activity of promoting CSPG degradation, inhibiting CSPG synthesis, or inhibiting CSPG sulfation (examples of such agents are: chondroitinase ABC, C6ST antisense agents, and GalNAc antisense agents); agents for treating and/or preventing COPD; methods for suppressing emphysematous lesions; and methods for treating and/or preventing COPD.

Abstract: The present invention examined the accumulation of chondroitin sulfate proteoglycans (CSPGs). The present invention relates to neurodegeneration-suppressing agents that are suitable for gene therapy or prevention of neural fibrotic degenerative diseases which induce neural cell death due to an accumulation of abnormal proteins, where the therapies are based on siRNAs against N-acetylgalactosamine-4-O-sulfotransferases (N-acetylgalactosamine-4-O-sulfotransferase-1, N-acetylgalactosamine-4-O-sulfotransferase-2, and N-acetylgalactosamine-4-sulfate 6-O-sulfotransferase (GalNAc4ST-1, GalNAc4ST-2, and GALNAC4S-6ST, respectively)), which are sulfotransferases for acetylgalactosamine, a CSPG side chain, and chondroitinase ABC, an enzyme that degrades chondroitin sulfate, another CSPG side chain.

Abstract: This invention provides compositions of highly phosphorylated lysosomal enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases.

Abstract: The invention relates to a method for the production of a medicament containing a polypeptide comprising at least one recombinant carbohydrate-binding polypeptide, or a functional fragment or derivative of said carbohydrate-binding polypeptide in a form stable for storage. The polypeptide mentioned comprises polypeptides or functional derivatives thereof, which are fused with cytotoxically effective peptides to give fusion proteins, or which are linked to another polypeptide having a cytotoxic activity. Moreover, the invention describes further formulating of the disclosed medicaments to medicaments with different pharmaceutical forms.

Abstract: The present invention is directed to compositions and methods for preventing or inhibiting biofilm formation on a solid substrate comprising an antimicrobial agent and a biofilm-degrading enzyme embedded in a matrix material.

Abstract: The invention relates to enzymes having xylanase, mannanase and/or glucanase activity, e.g., catalyzing hydrolysis of internal ?-1,4-xylosidic linkages or endo-?-1,4-ghicanase linkages; and/or degrading a linear polysaccharide beta-1,4-xylan into xylose. Thus, the invention provides methods and processes for breaking down hemicellulose, which is a major component of the cell wall of plants, including methods and processes for hydrolyzing hemicelluloses in any plant or wood or wood product, wood waste, paper pulp, paper product or paper waste or byproduct. In addition, methods of designing new xylanases, mannanases and/or glucanases and methods of use thereof are also provided. The xylanases, mannanases and/or glucanases have increased activity and stability at increased pH and temperature.

Abstract: Metallo-proteins including but not limited to lactoferrin (LF), transferrin (TF) and ovotransferrin (OTF) (all members of transferrin family), ceruloplasmin (CP) and metallo-thionein (MT) were found to stabilize and enhance the bio-functional activity of tocotrienol (T3), T3 mixtures or derivates. The synergism between MP and T3 also promote the intestinal transfer and the ultimate bio-availability of T3 and T3-derivatives for physiological functions. Such functional synergism includes hypocholesterolemic, anti-thrombotic, antioxidant, anti-athermogenic, anti-inflammatory and immuno-regulatory activities of T3 agents. These T3 compositions are useful as pharmaceuticals, in cosmetics, in foods and as nutritional supplements.

Abstract: The present invention relates to compositions and methods for the reduction of atherosclerotic plaques and the decrease in the level of total serum cholesterol, triglycerides, serum LDL cholesterol, and serum HDL cholesterol.

Abstract: The invention relates to the discovery of a novel Chondroitinase Glycoproteins (CHASEGP's), methods of manufacture, and potential uses in conditions where removal of chondroitin sulfates may be of therapeutic benefit. Chondroitinase Glycoproteins require both a substantial portion of the catalytic domain of the CHASEGP polypeptide and asparagine-linked glycosylation for optimal chondroitinase activity. The invention also includes carboxy-terminal deletion variants of CHASEGP that result in secreted variants of the protein to facilitate manufacture of a recombinant CHASEGP. Further described are suitable formulations of a substantially purified recombinant CHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. CHASEGP is useful for the degradation of glycosaminoglycans and chondroitin sulfate proteoglycans under clinical conditions where their removal is of therapeutic value.

Abstract: A thermostable glycosidase enzymes derived from various Thermococcus, Staphylothermus and Pyrococcus organisms is disclosed. The enzymes are produced from native or recombinant host cells and can be utilized in the food processing industry, pharmaceutical industry and in the textile industry, detergent industry and in the baking industry.

Abstract: The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.